Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Many investors and some analysts welcomed the move, seeing it as a sign that Summit's co-CEOs expect the company's shares to rise. But before deciding to jump on the bandwagon, it's essential to look ...

Veteran actress Sharmila Tagore's early-stage lung cancer diagnosis has brought attention to zero-stage lung cancer, also known as carcinoma in situ.

G12D-selective inhibitor zoldonrasib encouraged both the company and the analysts. Initial study data produced a 61% ...

Meanwhile, AstraZeneca's Imfinzi (durvalumab) plus chemo is being tested as an adjuvant therapy for stage II-III NSCLC, regardless of PD-L1 status, in the MERMAID-1 trial. Image Phil Taylor ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...